Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The Company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The Company’s subsidiaries include Doctor Morepen Limited, Total Care Limited, Morepen Inc. and MorepenMax Inc.

Adamis Pharmaceuticals Corporation company was founded in 2006 and is based in Del Mar, California. Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company’s wholly owned subsidiary, Biosyn, Inc. has a portfolio of product candidates known as microbicides. Biosyn’s product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally. Biosyn’s product candidates include Savvy, which underwent Phase III clinical trials in Ghana and Nigeria for reduction in the transmission of human immunodeficiency virus/acquired immunodeficiency disease, (HIV/AIDS). Effective April 1, 2009, Cellegy Pharmaceuticals, Inc. merged with Adamis Pharmaceuticals Corporation, pursuant to which Adamis Pharmaceuticals Corporation (Adamis) became a wholly owned subsidiary of the Company.

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company's primary product includes Tyzeka/Sebivo for the treatment of hepatitis B virus. It also develops IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS). In addition, Idenix Pharmaceuticals, Inc. focuses on the development of drugs for the treatment of hepatitis C virus. It has a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize its NNRTI compounds, including IDX899 for the treatment of HIV/AIDS. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.

Nature's Way Holding Company manufactures and markets nutritional supplements and other OTC products which are sold with the Enzymatic Therapy, Nature's Way, and Remifemin labels through natural foods retailers and mass market retailers in the US. Its products are aimed to alleviate everything from sleeplessness to hot flashes and are distributed throughout the US and to more than 40 other countries. Its Integrative Therapeutics and Vitaline brands are sold through healthcare practitioners' offices. The company is a unit of German firm Dr. Willmar Schwabe Pharmaceuticals.

Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts. Dyax Corp. (Dyax) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company uses the drug discovery technology, known as phage display, to identify antibody, small protein and peptide compounds for clinical development. The Company’s product DX-88 (ecallantide), is in late stage clinical trial development in two separate indications. In addition to DX-88, the phage display technology has allowed Dyax to develop a substantial pipeline of drug candidates. In June 2008, the Company completed a second phase three study, known as EDEMA4.

Renovo was established in 2000 by Professor Mark Ferguson and Doctor Sharon O'Kane. Renovo had its way, that famous scar on Harry Potter would be gone in no time. The pharmaceutical company develops drug products designed to prevent scarring caused by skin or cosmetic surgeries, eye injuries, adhesions, tendon and ligament damage, and nerve damage (no word yet on if it helps treat the blemishes of boy wizards). Renovo's chief product is Juvista, a trial stage drug that is injected into the edges of wounds to help prevent scars. The company also has three other pre-clinical drug products in development: Juvidex (for scar improvement), Prevascar (scar reduction), and Zesteem (skin healing).

Soft Gel Technologies, Inc. company makes hermetically sealed gelatin encapsulations of dietary supplements -- vitamins, minerals, fatty acids, and herbal extracts. The company manufactures more than 150 products, both private label and branded, to promote digestive health, immune system support, urinary tract wellness, and weight loss. Its brands include Carnisol, Femalgen, GlucoFit, and LyCoQ. Soft Gel Technologies also provides contract research and development, formulation, manufacturing, and sales and marketing services for other nutritional products companies. Soft Gel company is owned by Japanese chemicals firm Kenko.

Spectral Diagnostics Inc. company was founded in 1991 and is based in Toronto, Canada. Spectral Diagnostics Inc. operates in the in vitro diagnostic testing market. The company focuses on the development, manufacture, and sale of diagnostic tests that provide information to physicians. Its products include EAA Endotoxin Activity Assay, a diagnostic test in the field of sepsis; and RapidWN West Nile Virus IgM Test, an assay that helps physicians in obtaining diagnostic information regarding exposure to the West Nile virus. The company also offers other proprietary biochemicals, including monoclonal antibodies and recombinant proteins. Spectral Diagnostics Inc. has operations primarily in Canada, the United States, and Europe.

Shionogi & Co. wants to kill it like a shinobi (i.e. ninja) in the night. The Japanese drug firm is a leading maker of antibiotics in its home country, with a full lineup of oral and injectable anti-infectives. It has been expanding its pipeline and its portfolio of marketed products to encompass other therapeutic areas as well, with programs in metabolic conditions and pain management. Through partnerships with large global firms, it owns Japanese market rights to some big name drugs, including AstraZeneca's blood pressure drug Crestor (which Shionogi helped develop); Purdue Pharma's pain therapy OxyContin; and Merck & Co. allergy medication Claritin.

Unigene Laboratories, Inc. company was founded in 1980 and is based in Boonton, New Jersey. Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States. The company focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including nasal and oral calcitonin, and oral parathyroid hormone (PTH). It offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. Unigene Laboratories has licensing agreements with GlaxoSmithKline to develop an oral formulation of an analog of PTH; Upsher-Smith Laboratories, Inc. to market Fortical; Novartis Pharma AG to manufacture calcitonin; and Shijiazhuang Pharmaceutical Group for research, development, and manufacture of recombinant salmon calcitonin and non-oral PTH.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.